Carterra unveiled the Vega platform to scale surface plasmon resonance (SPR) to tens of thousands of interactions per day, positioning label‑free binding kinetics earlier in discovery workflows. Tim Germann, Carterra’s chief commercial officer, said Vega enables SPR to move from downstream validation into primary screening by delivering high throughput without sacrificing kinetic detail. The platform could alter hit triage, accelerate off‑target profiling, and reduce downstream attrition by providing rich binding data during early compound selection. Adoption will depend on integration with automated screening pipelines and acceptance by medicinal chemistry groups that traditionally rely on orthogonal affinity assays.